Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease

Acute Graft-versus-Host Disease Clinical Trial

Official title:

A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00282503
• Other study ID #: Acute GvHD-1
• Status: Terminated
• Phase: Phase 3
• First received: January 24, 2006
• Last updated: August 14, 2017
• Start date: January 2006

Study information

• Verified date: August 2017
• Source: Mallinckrodt
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the safety and efficacy of ECP treatment combined with high dose corticosteroids versus high dose corticosteroids alone, in the treatment of patients with newly diagnosed acute GvHD (Grades II to III) that developed within 100 days following an allo HPCT.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 19
• Est. primary completion date: June 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent must be obtained prior to conducting any study procedure.

2. Patients must be greater than or equal to 18 years old and weigh greater than or equal to 40 kg (88 lb).

3. Patients must have received an allogeneic hematopoietic BMT or PBSCT with myeloablative or reduced-intensity conditioning and have a new onset of acute GvHD, Grades II to III, which includes the skin and developed within 100 days following an allo-HPCT.

4. Patients must have received an allogeneic hematopoietic BMT or PBSCT from a related or unrelated donor that is matched at a minimum at the HLA-A, -B, and -DR loci (i.e., at least a 6 out of 6 match). HLA-A and -B match should be determined by serologic testing, and HLA-DR should be matched by molecular methods.

5. Patients must be receiving only a calcineurin inhibitor at study entry as part of their acute GvHD prophylactic regimen. Patients may have received additional immunosuppressants for acute GvHD prophylaxis prior to study entry.

6. Patients must have a Karnofsky performance greater than or equal to 50.

7. Patients must be able and willing to comply with all study procedures.

8. Patients must receive, or must have received, the first corticosteroid dose of approximately 2.0 mg/kg/day but no more than 2.5 mg/kg/day (methylprednisolone equivalent) within 24 hours of the initial diagnosis of Grade II to III acute GvHD. (Up to 2.5 mg/kg/day is allowed for inadvertent dosing fluctuations for reasons other than lack of response.)

9. Female patients must be one of the following: postmenopausal, surgically incapable of bearing children, practicing an acceptable method of birth control (acceptable methods include hormonal contraceptives, intrauterine device, and spermicide and barrier). Abstinence or partner/spouse sterility may also qualify at the Investigator's discretion. If a female patient is of childbearing potential, she must have a negative urine pregnancy test at screening. Male patients must also commit to using adequate contraceptive precautions (condoms). All patients (both males and females of childbearing potential) must commit to using adequate contraceptive precautions throughout their participation in the study and for at least 3 months following their last ECP treatment.

Exclusion Criteria:

1. Patients who have been diagnosed with chronic GvHD, including de novo chronic GvHD, prior to 100 days following an allo-HPCT.

2. Patients who have received donor lymphocyte infusions.

3. Patients with uncontrolled life-threatening infections.

4. Patients who have a white blood cell (WBC) count < 1.5 x 10^9/L (1,500/mcL).

5. Patients who have a platelet count < 20.0 x 10^9/L (20,000/mcL), despite platelet transfusion.

6. Patients whose total bilirubin is greater than or equal to 22 mg/dL.

7. Patients who have an International Normalized Ratio (INR) greater than or equal to 2.

8. Patients who are enrolled in any concomitant investigation for the treatment of acute GvHD.

9. Patients who are unable to tolerate the extracorporeal volume shifts associated with ECP treatment due to the presence of any of the following conditions: uncompensated congestive heart failure, pulmonary edema, severe chronic obstructive pulmonary disease, severe asthma, renal failure, hepatic encephalopathy, or hepatorenal syndrome.

10. Female patients whose hemoglobin (Hgb) is < 8.5 g/dL or male patients whose Hgb is < 10.0 g/dL at screening, despite packed red blood cell transfusion.

11. Patients who have a poor tolerability of venipuncture or a lack of adequate venous access for required treatments and blood sampling.

12. Patients who have a known hypersensitivity or allergy to Oxsoralen (methoxsalen).

13. Patients who have a known hypersensitivity or allergy to both heparin and citrate products.

14. Female patients who are pregnant and/or lactating.

15. Patients who have co-existing melanoma, basal cell or squamous cell skin carcinoma, aphakia, photosensitive disease (e.g., porphyria, systemic lupus erythematosus, or albinism), white blood cell count > 25,000 cells/mm3, previous splenectomy, or coagulation disorders.

Related Conditions & MeSH terms

• Acute Graft-versus-Host Disease
• Graft vs Host Disease

Intervention

Drug:
• Methoxsalen+ECP, Methylprednisolone
Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen: Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period), Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days within a week, but there should never be > 4 days between the ECP treatments within a week.) Methylprednisolone will be started at 2mg/kg daily dose and may be tapered by reducing dose each week at the following reductions: Daily Dose (mg/kg) 1 1.5 2 1.0 3 0.70 4 0.50 5 0.40 6 0.30 7 0.20 8 0.10

Procedure:
• Ecp
ECP or Extra Corporeal Phototherapy will be used with UVADex

Locations

Country	Name	City	State
Australia	Royal Brisbane Women's Hospital	Brisbane
Australia	Saint Vincent's Hospital	Darlinghurst
Australia	Westmead Hospital	Westmead
Austria	Medical University of Vienna	Vienna
Belgium	Universite Catholique De Louvain	Brussels
Belgium	University Hospital Gasthuisberg	Leuven
Belgium	Centre Hopitalier Universitaire Sart Tilman Liege	Liege
Canada	Maisonneuve-Rosemont Hopital	Montreal
Canada	Royal Victoria Hospital	Montreal
Canada	Princess Margaret Hospital	Toronto	Ontario
Canada	Vancouver General Hopsital	Vancouver	British Columbia
France	Centre Hospitalier Universitaire Hospital Bordeaux	Bordeaux
France	St. Louis Hospital	Paris
Germany	University of Dresden	Dresden
Germany	Klinikum der Universitat Erlangen-Nurnberg	Erlangen
Germany	Universitats Hautklinik	Essen
Germany	Universitatskrankenhaus Hamburg-Eppendorf	Hamburg
Germany	University of Koln	Koln
Germany	Universitatsklinikum Leipzig	Leipzig
Germany	Ludwig-Maximillians-Universitat Munchen	Munchen
Germany	Universitat Regensburg	Regensburg
Germany	University of Rostock	Rostock
Germany	Stammzelltransplantationzentrum der Universitat Wurzbrug	Wurzburg
Italy	San Martino Hospital	Genova
Italy	Universita di Siena Policlinico Le Scotte	Sienna
Netherlands	Utrecht University Medical Center	Utrecht
Switzerland	Kantonsspital Basel	Basel
United Kingdom	Hammersmith Hospital	London
United Kingdom	Royal Victoria Infirmary	Newcastle
United Kingdom	Rotheram General Hospital	Rotheram Yorkshire
United States	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan
United States	University of Florida	Gainesville	Florida
United States	Weill Medical College of Cornell University	New York	New York
United States	Thomas Jefferson University	Philadelphia	Pennsylvania
United States	Leukemia and Bone Marrow Transplant Center - Avera Cancer Institute	Sioux Falls	South Dakota

Sponsors (2)

Lead Sponsor	Collaborator
Mallinckrodt	PRA Health Sciences

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Belgium,  Canada,  France,  Germany,  Italy,  Netherlands,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To compare the safety and efficacy of ECP treatment combined with high dose corticosteroids versus high dose corticosteroids alone, in patients with newly diagnosed acute GvHD (Grades II to III) that developed within 100 days following an allo HPCT.	The primary efficacy analysis will be performed on the primary endpoint. The primary efficacy variable in this study is complete resolution of acute GvHD, defined as less than Grade I acute GvHD, according to the Glucksberg-Seattle criteria.	8 weeks